Westminster CA – February 6, 2018 – BioLargo Inc. (OTCQB:
BLGO) (the “Company”), an innovator of sustainable science and technology and
full-service environmental engineering company, announced today the completion
of a study that demonstrates the effectiveness of its Advanced Oxidation System
(“AOS”) water treatment platform for treatment of poultry wastewater and
municipal tertiary wastewater. The study was partially funded by the
Metropolitan Water District (“MWD”) of Southern California’s Innovative
Conservation Program (“ICP” - http://mwdh2o.com/ICP). A report of the study’s conclusions can be found
online at MWD’s ICP website, at http://www.bewaterwise.com/ICP_projects.shtml.
To highlight the report, the AOS was shown to:
- To be at least 50% more energy-efficient in comparison to incumbent technologies (U.V. and Ozone);
- Be forecasted to involve far less maintenance cost than chlorination; and
- Could present an effective and cost-efficient alternative to market-available tertiary treatment technologies, and stands to afford major water and costs savings to the Californian municipal wastewater market
These results complement the AOS’s prior proof-of-claim
results that prove the AOS can:
- Completely remove polyaromatic hydrocarbons;
- Inactivate 6 logs of bacterial pathogens (Salmonella enterica and Escherichia coli);
- Inactivate 4 logs of virus surrogate; and
- Remove naphthenic acids (up to 80% in single pass)
BioLargo President and Chief Executive Officer Dennis
Calvert commented, “This report demonstrates the enormous cost and water
recycling benefits the AOS will have for end-users. We recently acquired a
world-class team of engineers (www.BioLargoEngineering.com), to provide
problem-solving solutions for clients and support the scale-up and commercial
preparation for the AOS already underway. We are also evaluating a number of
strategic alliance, public funding opportunities, pilots and customer opportunities
for our AOS technology.”
About BioLargo, Inc.
BioLargo, Inc. is an innovator of sustainable science and
technology, and full-service environmental engineering company that makes life
better by delivering world-class products and services across a broad range of
industries, with a drive to deliver clean water, clean air and advanced wound
care. More information can be found about the company at www.BioLargo.com. Its engineering division (www.BioLargoEngineering.com)
features an exceptional team of experienced specialists dedicated to integrity,
reliability, safety, and environmental stewardship. It water division (www.BioLargoWater.com) showcases its
emerging technology, the Advanced Oxidation System “AOS”, an award-winning
product, having been awarded more than 55 research grants and counting,
specifically designed to eliminate common, troublesome, and dangerous
contaminants in water in a fraction of the time and cost of current
technologies. Its odor division features sustainable odor elimination products
including its CupriDyne Clean (www.CupriDyne.com)
Industrial Odor Eliminator, a product currently serving the leading solid waste
handling and wastewater treatment companies as well as any industry that that
contends with malodors, VOC’s or similar air quality related problems. Its
personal care product division features products in the pet, equine, military
supply and consumer markets, and include the Nature’s Best Solution® and
Deodorall® brands (www.OdorNoMore.com).
Its medical division (www.ClyraMedical.com)
focuses on advanced wound care management, featuring effective and gentle
solutions for chronic infected wounds and other uses to promote infection
control and regenerative tissue therapy. BioLargo also owns a 50% interest in
the Isan System, a fully automated iodine dosing system being commercialized
under a license to Clarion Water, Inc (www.ClarionWater.com).
Safe Harbor Statement
The statements contained herein, which are not historical,
are forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, the risks and
uncertainties included in BioLargo’s current and future filings with the Securities
and Exchange Commission, including those set forth in BioLargo’s Annual Report
on Form 10-K.
Company Contact
Dennis Calvert
President and CEO
BioLargo, Inc.
949-643-9540 x2
